With the outbreak of the SARS-CoV-2 (COVID-19) virus worldwide since December 2019, tocilizumab has become the subject of multiple studies due to its potential anti-inflammatory activity against the “cytokine storm” caused by the virus.  Read our review of the latest publications on COVID-19 and tocilizumab here. 

Cytokine storms and the use of Tocilizumab for treatment of COVID-19